Cancer Genetics Announces Distribution Partnership with Nikon Instruments

By Marie Michellod in : News // May 8 2013

Cancer Genetics, Inc.’s (OTCQB: CGIX) (“CGI” or the “Company”) wholly-owned subsidiary, Cancer Genetics Italia, S.r.l. (“CGI Italia”), has entered into an agreement with Nikon Instruments S.p.A. (“Nikon”) for the distribution of oncology-focused DNA Probes intended for fluorescence in situ hybridization (“FISH”) in the Italian market. This new partnership extends CGI’s global distribution network and provides [...]

Cancer Genetics Launches Proprietary Microarray for Kidney Cancer

By Marie Michellod in : News // May 2 2013

UroGenRA™-Kidney was designed and developed at Cancer Genetics to assist in the diagnosis and treatment selection of kidney cancer. Clinical Laboratory Improvement Amendments (CLIA) & New York State approvals of the microarray as a laboratory developed test (LDT) expand CGI’s menu of proprietary molecular diagnostic tests for urogenital and hematological cancers. Rutherford, May 2, [...]

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

By Jamie Thalmann in : Uncategorized // Apr 4 2013

RUTHERFORD, NJ (April 4, 2013): Cancer Genetics, Inc., a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the initial public offering [...]